New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
07:10 EDTCLDNCelladon announces in-license of stem cell factor development program
Celladon announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene, or mSCF, for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells. Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested mSCF gene therapy to reverse heart damage following myocardial infarction in animal models. Celladon plans to commence further preclinical work, building on available data from Mount Sinai in myocardial infarction.
News For CLDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent CLDN news | >>
April 27, 2015
12:25 EDTCLDNOn The Fly: Top stock stories at midday
Subscribe for More Information
10:04 EDTCLDNHigh option volume stocks
Subscribe for More Information
10:00 EDTCLDNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 3D Systems (DDD) downgraded to Hold from Buy at Canaccord... Akorn (AKRX) downgraded to Neutral from Overweight at Piper Jaffray... Allegiant Travel (ALGT) downgraded to Fair Value from Buy at CRT Capital... Altera (ALTR) downgraded to Neutral from Outperform at Baird... Amazon.com (AMZN) downgraded on valuation at Argus... American Science & Engineering (ASEI) downgraded to Sell from Fair Value at CRT Capital... Basic Energy (BAS) downgraded to Underperform from Neutral at Macquarie... C.H. Robinson (CHRW) downgraded to Sell from Neutral at UBS... Celladon (CLDN) downgraded to Neutral from Buy at Roth Capital... DST Systems (DST) downgraded to Neutral from Outperform at Credit Suisse... DeVry (DV) downgraded on weaker than expected outlook at Stifel... Eaton Vance (EV) downgraded to Sell from Neutral at Citigroup... Emerge Energy (EMES) downgraded to Hold from Buy at Wunderlich... FMC Technologies (FTI) downgraded to Accumulate from Speculative Buy at Global Hunter... Fibria Celulose (FBR) downgraded to Underweight from Equal Weight at Morgan Stanley... Forum Energy (FET) downgraded to Neutral at Baird... Gulf Island Fabrication (GIFI) downgraded to Hold from Accumulate at Johnson Rice... Hancock Holding (HBHC) downgraded to Hold from Buy at Drexel Hamilton... Hi-Crush Partners (HCLP) downgraded to Hold from Buy at Wunderlich... Houghton Mifflin (HMHC) downgraded to Neutral from Buy at Citigroup (Friday)... Infosys (INFY) downgraded to Hold from Buy at Deutsche Bank... Marvell (MRVL) downgraded to Hold from Buy at Craig-Hallum... Merge Healthcare (MRGE) downgraded to Hold from Buy at Topeka... Oceaneering (OII) downgraded to Neutral from Buy at Goldman... Omega Healthcare (OHI) downgraded at BofA/Merrill... Perrigo (PRGO) downgraded to Neutral from Buy at UBS... Petrobras (PBR) downgraded to Underweight from Equal Weight at Morgan Stanley... Procter & Gamble (PG) downgraded on lack of upside at CLSA... ResMed (RMD) downgraded to Neutral from Buy at Goldman... Seadrill (SDRL) downgraded to Sell from Neutral at Citigroup... Six Flags (SIX) downgraded to Neutral from Buy at Goldman... Stratasys (SSYS) downgraded to Hold at Canaccord... Telecom Italia (TI) downgraded to Neutral from Buy at BofA/Merrill... Twitter (TWTR) downgraded to Neutral from Buy at SunTrust... United Continental (UAL) downgraded to Fair Value from Buy at CRT Capital... Virgin America (VA) downgraded to Sell from Buy at CRT Capital.
09:36 EDTCLDNActive equity options trading on open
Subscribe for More Information
09:22 EDTCLDNOn The Fly: Pre-market Movers
Subscribe for More Information
08:55 EDTCLDNuniQure should be bought on weakness after Celladon failure, says Roth Capital
Subscribe for More Information
08:17 EDTCLDNbluebird bio, uniQure slide after Celladon trial misses endpoints
Subscribe for More Information
07:21 EDTCLDNCelladon downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
06:32 EDTCLDNCelladon downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded Celladon to Neutral with a $2 price target following neagive results for CUPID2 Trial of MYDICAR in advanced heart failure.
06:03 EDTCLDNStocks with implied volatility above IV index mean; CLDN WETF
Stocks with implied volatility above IV index mean; Celladon (CLDN) 419, WisdomTree (WETF) 76 according to iVolatility.
April 26, 2015
17:08 EDTCLDNCelladon reports Mydicar trial did not meet primary and secondary endpoints
Celladon announced that its phase 2b Cupid2 trial did not meet its primary and secondary endpoints. Cupid2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent Mydicar, or AAV1/SERCA2a, versus placebo added to a maximal, optimized heart failure drug and device regimen. In the study, the primary endpoint comparison resulted in a hazard ratio of 0.93, defined as heart failure-related hospitalizations or ambulatory treatment for worsening heart failure. The secondary endpoint comparison, defined as all-cause death, need for a mechanical circulatory support device, or heart transplant, likewise failed to show a significant treatment effect. The efficacy endpoint analyses were performed on the 243 modified intent to treat population, which excludes clinical events that occurred in patients who did not receive Mydicar or placebo, or which occurred prior to dosing. All other exploratory efficacy endpoints were also inconsistent with a treatment effect. No safety issues were noted.
April 24, 2015
05:55 EDTCLDNStocks with implied volatility above IV index mean; CLDN WETF
Subscribe for More Information
April 23, 2015
10:00 EDTCLDNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:18 EDTCLDNCelladon initiated with a Market Perform at BMO Capital
Subscribe for More Information
05:58 EDTCLDNStocks with implied volatility above IV index mean; CLDN AMZN
Stocks with implied volatility above IV index mean; Celladon (CLDN) 383, Amazon.com (AMZN) 44 according to iVolatility.
April 22, 2015
13:55 EDTCLDNCelladon May options active into trial outcome
Subscribe for More Information
April 20, 2015
15:11 EDTCLDNCelladon call volume and volatility elevated into trial outcome
Subscribe for More Information
April 16, 2015
07:51 EDTCLDNCelladon volatility elevated into trial outcome
Subscribe for More Information
April 15, 2015
10:31 EDTCLDNOptions with increasing implied volatility:
Options with increasing implied volatility: CLDN PNK TLM FOSL ARCP CSCO
April 14, 2015
10:50 EDTCLDNOptions with increasing implied volatility
Subscribe for More Information
1 | 2 | all recent CLDN news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use